These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 3459574)

  • 1. Pharmacokinetics of aclarubicin and its metabolites in humans and their disposition in blood cells.
    Ando S; Nakamura T; Kagawa D; Ueda T; Nishimura T; Kubo A; Tsutani H; Sasada M; Uchino H
    Cancer Treat Rep; 1986 Jul; 70(7):835-41. PubMed ID: 3459574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacokinetics and action mechanism of anthracyclines].
    Fukushima T; Ueda T; Nakamura T
    Gan To Kagaku Ryoho; 1992 Apr; 19(4):445-50. PubMed ID: 1558393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between the intracellular accumulation of anthracyclines and effectiveness in vitro and in vivo.
    Tapiero H; Munck JN; Fourcade A
    Drugs Exp Clin Res; 1986; 12(1-3):257-64. PubMed ID: 3460752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular accumulation and disposition of aclacinomycin A.
    Egorin MJ; Clawson RE; Ross LA; Schlossberger NM; Bachur NR
    Cancer Res; 1979 Nov; 39(11):4396-400. PubMed ID: 498071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of erythrocyte-bound daunorubicin in patients with acute leukemia.
    Skorokhod OA; Garmaeva TTs; Vitvitsky VM; Isaev VG; Parovichnikova EN; Savchenko VG; Ataullakhanov FI
    Med Sci Monit; 2004 Apr; 10(4):PI55-64. PubMed ID: 15039656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular pharmacokinetics of aclacinomycin A in cultured L1210 cells. Comparison with daunorubicin and doxorubicin.
    Zenebergh A; Baurain R; Trouet A
    Cancer Chemother Pharmacol; 1982; 8(2):243-9. PubMed ID: 6955072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction of aclarubicin with DNA as compared with daunorubicin and doxorubicin.
    Ando S; Sasada M; Uchino H; Kagawa D; Ueda T; Nakamura T
    Nihon Gan Chiryo Gakkai Shi; 1986 Dec; 21(10):2343-55. PubMed ID: 3471823
    [No Abstract]   [Full Text] [Related]  

  • 8. Effects of aclacinomycin on cell survival and cell cycle progression of cultured mammalian cells.
    Traganos F; Staiano-Coico L; Darzynkiewicz Z; Melamed MR
    Cancer Res; 1981 Jul; 41(7):2728-37. PubMed ID: 6166368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overview of progress in hematology in 1981 with special reference to leukocyte.
    Kimura K
    Nihon Ketsueki Gakkai Zasshi; 1982 Feb; 45(1):1-10. PubMed ID: 7051724
    [No Abstract]   [Full Text] [Related]  

  • 10. [Pharmacokinetic study of aclarubicin. The pharmacokinetics of the preparation and its biologically active metabolites in the blood of rats].
    Geodakian SV; Firsov AA; Fomina IP
    Antibiot Med Biotekhnol; 1987 Oct; 32(10):768-72. PubMed ID: 3480699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I-II study of aclarubicin for treatment of acute myeloid leukemia.
    Machover D; Gastiaburu J; Delgado M; Goldschmidt E; Hulhoven R; Misset JL; de Vassal F; Tapiero H; Ribaud P; Schwarzenberg L
    Cancer Treat Rep; 1984 Jun; 68(6):881-6. PubMed ID: 6587933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacokinetic study of aclarubicin. The distribution of the preparation and its biologically active metabolites in rat tissues].
    Firsov AA; Geodakian SV; Egorov LV; Terent'eva TG
    Antibiot Med Biotekhnol; 1987 Oct; 32(10):773-7. PubMed ID: 3480700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of some anthracycline antibiotics in an in vivo model for studying drug-induced human leukemia cell differentiation.
    Schwartz EL; Brown BJ; Nierenburg M; Marsh JC; Sartorelli AC
    Cancer Res; 1983 Jun; 43(6):2725-30. PubMed ID: 6573951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II evaluation of aclarubicin in refractory adult acute leukemia: a Southwest Oncology Group Study.
    Dabich L; Bull FE; Beltran G; Athens JW; Coltman CA; Weick JK; Van Slyck EJ; Amare M
    Cancer Treat Rep; 1986 Aug; 70(8):967-9. PubMed ID: 3460700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytofluorescence localization of anthracycline antibiotics.
    Egorin MJ; Clawson RE; Cohen JL; Ross LA; Bachur NR
    Cancer Res; 1980 Dec; 40(12):4669-76. PubMed ID: 6934029
    [No Abstract]   [Full Text] [Related]  

  • 16. Phase I--II evaluation of a new anthracycline antibiotic, aclacinomycin A, in adults with refractory leukemia.
    Warrell RP; Arlin ZA; Kempin SJ; Young CW
    Cancer Treat Rep; 1982 Aug; 66(8):1619-23. PubMed ID: 6955022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparative evaluation of a combination of daunorubicin and cytosine arabinoside and that of aclarubicin and cytosine arabinoside in remission induction in acute non-lymphocytic leukemia].
    Takahashi I; Hara M; Ohmoto E; Oda Y; Endo Y; Fujimoto S; Uchida K; Takaoka K; Watanabe S; Lai M; Kohi F; Kitajima K; Kimura I; Sanada H; Tokioka M; Adachi T; Yorimitsu S
    Gan To Kagaku Ryoho; 1982 Sep; 9(9):1617-22. PubMed ID: 6964050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of N4-behenoyl-1-beta-D-arabinofuranosylcytosine in patients with acute leukemia.
    Ueda T; Nakamura T; Ando S; Kagawa D; Sasada M; Uchino H; Johno I; Akiyama Y
    Cancer Res; 1983 Jul; 43(7):3412-6. PubMed ID: 6850647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I study of idarubicin hydrochloride in patients with acute leukemia. The Idarubicin Study Group of Japan.
    Tamura K
    Semin Hematol; 1996 Oct; 33(4 Suppl 3):2-11. PubMed ID: 8916310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uptake, efflux, and hydrolysis of aclacinomycin A in Friend leukemia cells.
    Fourcade A; Farhi JJ; Bennoun M; Tapiero H
    Cancer Res; 1982 May; 42(5):1950-4. PubMed ID: 6950813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.